Loading...

Biophytis

BST:6XB
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6XB
BST
€22M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biophytis SA, a biotechnology company, engages in the development of therapeutic solutions for treating age-related degenerations. The last earnings update was 170 days ago. More info.


Add to Portfolio Compare Print Invest
6XB Share Price and Events
Price Volatility
6XB
Industry
5yr Volatility vs Market
Related Companies

6XB Value

 Is Biophytis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biophytis. This is due to cash flow or dividend data being unavailable. The share price is €2.31.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biophytis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biophytis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:6XB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in EUR €-1.24
ENXTPA:ALBPS Share Price ** ENXTPA (2018-07-17) in EUR €1.65
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 31.17x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biophytis.

BST:6XB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALBPS Share Price ÷ EPS (both in EUR)

= 1.65 ÷ -1.24

-1.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biophytis is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biophytis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biophytis's expected growth come at a high price?
Raw Data
BST:6XB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
36.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.61x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

BST:6XB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -1.33x ÷ 36.3%

-0.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biophytis is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biophytis's assets?
Raw Data
BST:6XB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in EUR €1.58
ENXTPA:ALBPS Share Price * ENXTPA (2018-07-17) in EUR €1.65
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.86x
BST:6XB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALBPS Share Price ÷ Book Value per Share (both in EUR)

= 1.65 ÷ 1.58

1.04x

* Primary Listing of Biophytis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biophytis is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biophytis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biophytis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6XB Future Performance

 How is Biophytis expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biophytis expected to grow at an attractive rate?
  • Biophytis's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Biophytis's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Biophytis's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:6XB Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:6XB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 36.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:6XB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:6XB Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 0 1
2021-12-31 0 1
2020-12-31 0 -5 -7 2
2019-12-31 13 12 11 2
2018-12-31 0 -9 -10 2
BST:6XB Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2017-12-31 -9 -11
2017-09-30 -9 -10
2017-06-30 -9 -9
2017-03-31 -8 -9
2016-12-31 -7 -8
2016-09-30 -6 -8
2016-06-30 -5 -7
2016-03-31 -4 -6
2015-12-31 -3 -5
2015-09-30 -2 -4
2015-06-30 -1 -2
2015-03-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biophytis's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Biophytis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:6XB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Biophytis Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:6XB Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 -0.49 -0.49 -0.49 1.00
2019-12-31 0.81 0.81 0.81 1.00
2018-12-31 -0.91 -0.76 -1.05 2.00
BST:6XB Past Financials Data
Date (Data in EUR Millions) EPS *
2017-12-31 -1.24
2017-09-30 -1.30
2017-06-30 -1.39
2017-03-31 -1.34
2016-12-31 -1.28
2016-09-30 -1.24
2016-06-30 -1.19
2016-03-31 -1.14
2015-12-31 -1.08
2015-09-30 -0.85
2015-06-30 -0.56
2015-03-31 -0.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biophytis is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Biophytis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biophytis has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6XB Past Performance

  How has Biophytis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biophytis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biophytis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biophytis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biophytis's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biophytis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biophytis Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:6XB Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 -11.41 2.87 7.04
2017-09-30 -10.33 2.77 6.37
2017-06-30 -9.25 2.68 5.71
2017-03-31 -8.60 2.75 5.41
2016-12-31 -7.95 2.82 5.12
2016-09-30 -7.59 3.11 4.44
2016-06-30 -7.22 3.40 3.75
2016-03-31 -6.23 3.24 2.86
2015-12-31 -5.23 3.07 1.97
2015-09-30 -3.67 2.17 1.33
2015-06-30 -2.11 1.27 0.69
2015-03-31 -1.41 0.87 0.45
2014-12-31 -0.71 0.46 0.20
2013-12-31 -0.52 0.57 -0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biophytis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biophytis has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biophytis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biophytis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biophytis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6XB Health

 How is Biophytis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biophytis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biophytis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biophytis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biophytis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biophytis Company Filings, last reported 9 months ago.

BST:6XB Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 21.19 1.01 19.86
2017-09-30 21.19 1.01 19.86
2017-06-30 7.00 1.07 4.39
2017-03-31 7.00 1.07 4.39
2016-12-31 4.52 1.09 3.07
2016-09-30 4.52 1.09 3.07
2016-06-30 8.25 0.50 6.81
2016-03-31 8.25 0.50 6.81
2015-12-31 11.60 0.80 9.41
2015-09-30 11.60 0.80 9.41
2015-06-30 -2.21 2.55 1.60
2015-03-31 -2.21 2.55 1.60
2014-12-31 -1.13 0.72 0.01
2013-12-31 -0.41 0.46 0.04
  • Biophytis's level of debt (4.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Biophytis's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biophytis has sufficient cash runway for 2.8 years based on current financial obligations.
  • Biophytis has sufficient cash runway for more than 3 years if financial obligations continue to grow at historical rates of 65.4% each year.
X
Financial health checks
We assess Biophytis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biophytis has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6XB Dividends

 What is Biophytis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biophytis dividends.
If you bought €2,000 of Biophytis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biophytis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biophytis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:6XB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:6XB Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biophytis has not reported any payouts.
  • Unable to verify if Biophytis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biophytis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biophytis has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Biophytis's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Biophytis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biophytis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biophytis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6XB Management

 What is the CEO of Biophytis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stanislas Veillet, image provided by Google.
Stanislas Veillet
COMPENSATION €187,000
CEO Bio

Mr. Stanislas Veillet, Ph.D. serves as the Chairman of Management Board and Chief Executive Officer of Institut Biophytis SAS. Mr. Veillet served as Director of Research at Cargill. Mr. Veillet created Biophytis in 2006. Mr. Veillet is an Agronomist and a Doctor in genetics. Mr. Veillet worked for large multinational companies: Pharmacia and Danone. Mr. Veillet is an Expert in the areas of nutrition and health.

CEO Compensation
  • Stanislas's compensation has increased whilst company is loss making.
Management Team Tenure

Average tenure of the Biophytis management team in years:

0.8
Average Tenure
  • The average tenure for the Biophytis management team is less than 2 years, this suggests a new team.
Management Team

Stanislas Veillet

TITLE
Chairman of Management Board & CEO
COMPENSATION
€187K

Jean-Gérard Galvez

TITLE
Member of Management Board
COMPENSATION
€18K

Nadine Coulm

TITLE
Member of Management Board
COMPENSATION
€18K

Jean-Christophe Montigny

TITLE
Chief Financial Officer

Philippe Dupont

TITLE
Director of Operations
AGE
57
TENURE
2.8 yrs

Dimitri Batsis

TITLE
Member of Management Board
TENURE
0.8 yrs

Eric Rowinsky

TITLE
Member of Management Board
AGE
61
TENURE
0.8 yrs

René Lafont

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board

Samuel Agus

TITLE
Chief Medical Officer
TENURE
0.8 yrs

Waly Dioh

TITLE
Director of Clinical Development
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure of the Biophytis board of directors in years:

1.9
Average Tenure
  • The average tenure for the Biophytis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jean Mariani

TITLE
Member of Scientific Advisory Board

René Lafont

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board

José-Alain Sahel

TITLE
Member of Scientific Advisory Board

Thomas Voit

TITLE
Member of Scientific Advisory Board
TENURE
1 yrs

Ivana Kim

TITLE
Member of Scientific Advisory Board
TENURE
2.4 yrs

Roger Fielding

TITLE
Member of Scientific Advisory Board
TENURE
2.4 yrs

Jean Franchi

TITLE
Director
AGE
52
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
X
Management checks
We assess Biophytis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biophytis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6XB News

External News
Loading...
Simply Wall St News

6XB Company Info

Map
Description

Biophytis SA, a biotechnology company, engages in the development of therapeutic solutions for treating age-related degenerations. Its products under development include Sarconeos, a drug candidate that is Phase II b clinical trials for the treatment of sarcopenia; and Macuneos, an oral product, which is in Phase II b clinical trials for treating dry age-related macular degeneration. The company was founded in 2006 and is based in Paris, France.

Details
Name: Biophytis SA
6XB
Exchange: BST
Founded: 2006
€22,130,174
13,428,504
Website: http://www.biophytis.com
Address: Biophytis SA
Pierre et Marie Curie University – BC 9,
Bâtiment A 4ème étage,
Paris,
Ile-de-France, 75252,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALBPS Common Stock Euronext Paris FR EUR 13. Jul 2015
DB 6XB Common Stock Deutsche Boerse AG DE EUR 13. Jul 2015
BST 6XB Common Stock Boerse-Stuttgart DE EUR 13. Jul 2015
LSE 0D1W Common Stock London Stock Exchange GB EUR 13. Jul 2015
Number of employees
Current staff
Staff numbers
19
Biophytis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/14 18:52
End of day share price update: 2018/07/17 00:00
Last estimates confirmation: 2018/09/14
Last earnings filing: 2018/04/27
Last earnings reported: 2017/12/31
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.